News

PipelineReview.com1h
Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
BOTHELL, WA, USA I August 05, 2025 I Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the presentation of favorable safety and tolerability data from a ...
PipelineReview.com1h
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and ...
LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with ...
PipelineReview.com1h
Epicrispr Biotechnologies Doses First Patient in First-in-Human Clinical Trial of EPI-321 for Facioscapulohumeral Muscular Dystrophy
FDA has granted Fast Track, Rare Pediatric Disease, and Orphan Drug Designation for EPI-321 in FSHD SOUTH SAN FRANCISCO, CA, USA I August 05, 2025 I Epicrispr Biotechnologies, a clinical-stage company ...
PipelineReview.com1h
Fapon Biopharma Announces the enrollment of the First Patient in the Phase I Clinical Trial of FP008, A First-in-Class Immunotherapy for Solid Tumors
DONGGUAN, China I August 5, 2025 I Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the ...
PipelineReview.com1h
Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016
AMSTERDAM, The Netherlands; ZUG, Switzerland & GDAŃSK, Poland I August 05, 2025 I Polpharma Biologics S.A. (“Polpharma Biologics”) announces a global ...
PipelineReview.com1h
Hemispherian Receives FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1
OSLO, Norway I August 5, 2025 I Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, today announced ...